从未吸烟者肺癌:风险因素,驱动突变和治疗进展
Po-Ming Chen1,2, Yu-Han Huang3, Chia-Ying Li3
1Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
Diagnostics (Basel, Switzerland)
|January 28, 2026
概括
从未吸烟者肺癌 (LCINS) 与环境因素和独特的遗传突变有关. 了解这些独特的分子特征是开发向治疗和改善患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 环境健康 环境健康
- 遗传学 是一个遗传学.
背景情况:
- 从未吸烟者的肺癌 (LCINS) 是一个重要的全球健康问题,与吸烟相关的肺癌不同.
- LCINS是由环境致癌物和特定基因组改变之间的复杂相互作用引起的.
- 本综述侧重于环境风险,分子概况和LCINS.的治疗进展.
研究的目的:
- 审查与非吸烟者肺癌相关的环境风险因素.
- 在主要肺癌亚型中,识别和比较从不吸烟者与吸烟者的驱动突变.
- 根据分子分析,检查针对肺癌的向治疗方法的进展.
主要方法:
- 进行了关于非吸烟者肺癌风险因素研究的叙述性审查.
- 分析了小细胞肺癌,肺腺癌,状细胞癌和大细胞癌中驱动突变的研究.
- 进行了PubMed搜索第三阶段试验和向治疗研究 (2016-2025).
主要成果:
- 环境因素,如烟,,石棉,和PM2.5,通过氧化应激和炎症与LCINS有关.
- 从来没有吸烟的人表现出EGFR,PIK3CA,OS9,MET和STK11的特征突变,与吸烟者的TP53突变不同.
- 向疗法和免疫疗法显示出前景,突出显示了分子分析的必要性.
结论:
- LCINS是一个独立的实体,受到环境暴露和遗传敏感性的影响.
- 在LCINS的遗传变化有助于瘤免疫逃避,驱动癌症的进展.
- 改善空气质量,分子诊断和精准医学对于全球管理LCINS至关重要.
相关概念视频
Factors Affecting the Risk of Infection
13.4K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.4K
Therapeutic Drug Monitoring: Affecting Factors
210
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
210
Mutations
94.4K
Overview
94.4K
Mutations
44.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Cancers Originate from Somatic Mutations in a Single Cell
14.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K


